Home » BI’s OFEV Approved in Europe for Interstitial Lung Disease
BI’s OFEV Approved in Europe for Interstitial Lung Disease
The European Commission has approved Boehringer Ingelheim’s Ofev (nintedanib) for treatment of systemic sclerosis-associated interstitial lung disease.
The approval was based on results from a phase 3 clinical trial which showed that Ofev slowed the loss of pulmonary function in patients with the disease.
The FDA approved Ofev for systemic sclerosis-associated interstitial lung disease in September 2019.
Upcoming Events
-
18Jul
-
21Oct